Following a review of its approval as an active substance for use in PPP in GB, HSE has decided that mancozeb no longer meets the approval criteria set out in assimilated Regulation 1107/2009 (the Regulation). Further details can be found in the decision document (.pdf) and the GB approval register. On 10 January 2024 HSE issued an ebulletin that proposed withdrawal of the GB approval of mancozeb following a review that indicated it no longer met the approval criteria. The ebulletin referred to the next stage of the withdrawal process being consultation with trading partners via the World Trade Organisation (WTO). This consultation has now concluded. The GB Administrations have given consent for HSE to carry out the decision-making function arising from this review. Under the Regulation, an active substance does not meet the approval criteria if it has endocrine disrupting properties. In addition to the new knowledge that triggered the review, information provided by the producers and the comments that were made under the WTO process, were also taken into account. HSE has concluded that mancozeb does have endocrine disrupting properties and that the approval criteria are no longer met. The approval for mancozeb will therefore end at its current expiry date of 31 May 2024. To allow existing stocks to be removed from the supply chain safely, HSE has agreed a phased withdrawal programme: - producers will be permitted 6 months from the expiry date to sell and distribute authorised mancozeb products until 30 November 2024.
- users will be permitted a further 1 year to dispose of, store, and use existing stocks of authorised mancozeb products until 30 November 2025.
If you have any questions relating to this ebulletin, please contact us. | 
